megalencephaly-capillary malformation-polymicrogyria syndrome

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)	CLOVES syndrome, Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Lymphatic Abnormalities, angiomatosis, angioosteohypertrophic syndrome, cardiovascular disorder, lymphatic system disorder, megalencephaly-capillary malformation-polymicrogyria syndrome, vascular disorder, vascular malformation	Recruiting	Phase 2	2026-08-25		NCT06789913
Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)	Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, central nervous system malformation, hereditary disease, hereditary sensory and autonomic neuropathy, inherited neurodegenerative disorder, megalencephaly-capillary malformation-polymicrogyria syndrome, nervous system disorder, neurodegenerative disease, neurodevelopmental disorder, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, psychiatric disorder	Recruiting	Phase 2	2026-02-24		NCT05577754

Clinical trials